| Old Articles: <Older 6631-6640 Newer> |
|---|
 |
The Motley Fool
August 27, 2010
Jordan DiPietro |
AstraZeneca's Dividends May Not Last Forever AstraZeneca's payout ratio compared to its peers is a lower percentage, which illustrates that its dividend is probably more sustainable.   |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
August 27, 2010
Seth Jayson |
What's the Profitability Trend at Agilent Technologies? With recent TTM operating margins below historical averages, Agilent Technologies has some work to do. |
The Motley Fool
August 27, 2010
Travers & Jayson |
The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science. |
The Motley Fool
August 27, 2010
Brian Orelli |
Ignoring This Could Put Your Investment at Risk A couple of recent events should have you a little more focused on drugmakers' inventories. |
BusinessWeek
August 26, 2010
Peter Waldman |
Sutter Health's Market Power Is Questioned Insurers say the Northern California hospital chain uses its market clout to raise prices. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
BusinessWeek
August 26, 2010 |
Pockets of Profit in Health-Care Stocks Kris Jenner of the T. Rowe Price Health Sciences Fund on where to find lucrative product pipelines |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
The Motley Fool
August 26, 2010
Brian Orelli |
Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers. |
| <Older 6631-6640 Newer> Return to current articles. |
